Get the Stockscreener App
5.61
12.20%
0.61
After Hours:
5.54
-0.07
-1.25%
Sage Therapeutics Inc stock is traded at $5.61, with a volume of 4.31M.
It is up +12.20% in the last 24 hours and up +14.26% over the past month.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$5.00
Open:
$5.06
24h Volume:
4.31M
Relative Volume:
4.97
Market Cap:
$343.18M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
-0.5655
EPS:
-9.92
Net Cash Flow:
$-424.74M
1W Performance:
+4.18%
1M Performance:
+14.26%
6M Performance:
-47.42%
1Y Performance:
-73.13%
1-Day Range:
$4.95
$5.62
1-Week Range:
$4.94
$5.62
52-Week Range:
$4.62
$28.26
Sage Therapeutics Inc Stock (SAGE) Company Profile
Name
Sage Therapeutics Inc
Sector
Industry
Phone
617-299-8380
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare SAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
5.61 | 343.18M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-04-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-29-24 | Initiated | Citigroup | Sell |
| May-29-24 | Initiated | Robert W. Baird | Neutral |
| Apr-17-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Aug-08-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-08-23 | Downgrade | Goldman | Buy → Neutral |
| Aug-08-23 | Downgrade | Needham | Buy → Hold |
| Aug-07-23 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-07-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-07-23 | Downgrade | Stifel | Buy → Hold |
| Aug-07-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Mar-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Mar-31-22 | Initiated | Berenberg | Hold |
| Nov-02-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-16-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-07-21 | Initiated | Piper Sandler | Overweight |
| Feb-26-21 | Downgrade | Mizuho | Buy → Neutral |
| Feb-25-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Resumed | Raymond James | Mkt Perform |
| Jan-22-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-04-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-04-20 | Upgrade | Mizuho | Neutral → Buy |
| Dec-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-06-20 | Reiterated | H.C. Wainwright | Neutral |
| Sep-11-20 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-10-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-08-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-28-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-06-19 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-05-19 | Reiterated | Guggenheim | Buy |
| Dec-05-19 | Downgrade | SunTrust | Buy → Hold |
| Oct-30-19 | Initiated | H.C. Wainwright | Neutral |
| May-23-19 | Initiated | Wedbush | Outperform |
| Apr-25-19 | Initiated | Jefferies | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-11-18 | Initiated | Oppenheimer | Outperform |
View All
Sage Therapeutics Inc Stock (SAGE) Latest News
Postpartum Depression Therapeutics Market Size in the 7MM was ~USD 260 Million in 2023, is expected to grow by 2034, and estimates DelveInsight - The Globe and Mail
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Sage Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsSAGE - The Eastern Progress Online
Brokerages Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target at $11.53 - MarketBeat
Sage Therapeutics price target lowered to $6 from $10 at Stifel - Yahoo Finance
Where Sage Therapeutics Stands With Analysts - Benzinga
Stifel Nicolaus Has Lowered Expectations for Sage Therapeutics (NASDAQ:SAGE) Stock Price - MarketBeat
Sage Therapeutics' SWOT analysis: navigating challenges in CNS drug stock - Investing.com
Sage Therapeutics' SWOT analysis: navigating challenges in CNS drug stock By Investing.com - Investing.com UK
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online
Levi & Korsinsky Notifies Sage Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSAGE - The Eastern Progress Online
Layoff Tracker: Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff - BioSpace
Sage Therapeutics shares stay Neutral rated by Mizuho, target cut on discontinued pipeline - Investing.com UK
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Fmr LLC - MarketBeat
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class ActionSAGE - The Eastern Progress Online
Investors who lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class ActionSAGE - The Eastern Progress Online
Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seeking Recovery for InvestorsContact The Gross Law Firm - The Eastern Progress Online
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc.(SAGE) Shareholders - The Eastern Progress Online
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
RTW Investments LP Buys 111,123 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
RBC Capital Upgrades Sage Therapeutics (SAGE) - MSN
Deutsche Bank Initiates Coverage of Sage Therapeutics (SAGE) with Hold Recommendation - MSN
Sage Therapeutics, Inc. Announces Retirement of Jeffrey M. Jonas as Member of Board of Directors , Effective December 1, 2024 - Marketscreener.com
Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Member of Board of Directors , Effective December 1, 2024 - Marketscreener.com
SAGE (Sage Therapeutics) Change In Inventory : $0.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
SAGE (Sage Therapeutics) Cash Flow from Financing : $10.4 Mil (TTM As of Sep. 2024) - GuruFocus.com
Rx Rundown: Novartis, Sage Therapeutics, Eli Lilly and more - MM+M Online
Sage Therapeutics announces board member retirement By Investing.com - Investing.com Nigeria
Sage Therapeutics announces board member retirement - Investing.com India
Sage Therapeutics' SWOT analysis: stock faces hurdles amid CNS pipeline setbacks By Investing.com - Investing.com South Africa
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - BioSpace
Sage Therapeutics' SWOT analysis: stock faces hurdles amid CNS pipeline setbacks - Investing.com
Sage Therapeutics Inc Stock (SAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sage Therapeutics Inc Stock (SAGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| IGUCHI KIMI | CFO & Treasurer |
Jan 02 '24 |
Option Exercise |
1.36 |
1,642 |
2,233 |
70,429 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):